medinfo@exoxemis.com

Home/ Intellectual Property

Intellectual Property

Exoxemis offers a comprehensive intellectual property portfolio in myeloperoxidase (MPO) and eosinophil peroxidase (EPO) technologies. Protected by more than 20 patents worldwide, this portfolio covers research and development, manufacturing, formulation, and delivery.

Chemiluminescence Assay of In Vivo Inflammation

CountryPatent Number
U.S.A5,108,899
EPC0430440

Haloperoxidase Acid Optimum Chemiluminescence Assay System

CountryPatent Number
U.S.A5,556,758
EPC0421788
Israel95900
Germany690 28 591
Canada
Issued December 2003		2,026,809
Japan3184894
Ireland82106

Oxygen Activatable Formulations for Disinfection or Sterilization

CountryPatent Number
U.S.A5,756,090
U.S.A6,033,662
U.S.A
Issued January 2003		6,503,507
Australia708557
EPC
Issued July 2003		0832198

Treatment of Infection and the Control of Flora Using Haloperoxidase

CountryPatent Number
Australia663869
EPC0500387
Canada
Issued April 2003		2,061,601
Ireland
Issued September 2003		083079

Killing or Inhibition of Yeast and Sporular Microorganisms

CountryPatent Number
Australia679777
EPC0713527
Korea325,901
China83564
U.S.A.5,510,104
U.S.A.5,451,402
U.S.A5,389,369

The Prevention and Treatment of STDs

CountryPatent Number
U.S.A5,565,197
Australia684505
Korea306,968
EPC0693934
U.S.A5,718,896

Other Methods and Compositions Patents

CountryPatent Number
U.S.A5,888,505
U.S.A
Seminal patent issued September 2001		6,294,168
Australia703034
Israel100997

Myeloperoxidase Compositions & Methods for Inhibition of Lipopolysaccharides & Lipid A

CountryPatent Number
Mexico392701
EuropeanAllowed
Japan6713546
Canada3022426
Israel262930
Australia2017269582
ChinaZL201780032711.9
MacaoJ/006474
United States11,389,514
Hong KongPublished